Sulfonylurea Active Ingredients TRIZ Cases

Clinical data showed relacorilant can be co-administered with CYP2C9 substrates without dose reduction or the expected rise in plasma exposure.

Blocking SUR1-TRPM4 during mechanical thrombectomy helps limit cerebral edema and neurological decline in large ischemic stroke lesions.

Blocking SUR1-TRPM4 during mechanical thrombectomy helps limit brain edema, late deterioration, and mortality after large ischemic stroke.

This case uses a copovidone amorphous solid dispersion in capsules to address crystallization and poor oral bioavailability.

This case combines a glyburide loading bolus with prolonged infusion and PVC avoidance to maintain therapeutic levels for up to 72 hours.

Torasemide treats pulmonary edema in animals by maintaining efficacy while reducing resistance and side effects.

Low-temperature extrusion produces dust-free gliclazide granules, eliminating segregation risks and hazardous high-temperature processing steps.

Sulfonylurea receptor antagonists block harmful ion channels, preventing neuronal cell death and slowing Alzheimer's disease progression.

Matrix-based torsemide formulation extends diuretic duration while minimizing electrolyte imbalances in heart failure treatment.

Curcuma oil-based SNEDDS in 3D printed tablets overcomes poor aqueous solubility to improve drug dissolution rates.

Mannitol resolves solubility conflicts between lisinopril and torasemide, ensuring 85% dissolution within 15 minutes for high bioavailability.

Torasemide treats pulmonary edema in heart failure by bypassing furosemide resistance and reducing side effects.

Polyunsaturated fatty acid salts increase solubility by at least 100% for poorly soluble actives, overcoming low bioavailability limits.

Targeting ABCA1, ABCG1, and MDR1 transporters disrupts steroid production while minimizing adverse effects from broad-spectrum chemotherapy.